INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Ardelyx, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). The investigation concerns whether Ardelyx has violated the federal securities laws and/or engaged in other unlawful business practices.

On July 19, 2021, the Company announced that “it received a letter from the U.S. Food and Drug Administration (the “FDA”) on July 13, 2021, stating that, as part of its ongoing review of the Company’s New Drug Application (“NDA”) for the control of serum phosphorus in adult patients with chronic kidney disease (“CKD”) on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.” The Company further announced that it requested a meeting to discuss the deficiencies identified by the FDA and was notified that the request was denied. On this news, the price of Ardelyx’s stock declined by $5.69 per share, or approximately 73.9%, from $7.70 per share to close at $2.01 per share on July 20, 2021.

If you purchased or otherwise acquired Ardelyx securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [e-mail], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.